

Hannah De Schutter¹, Julie Hias^{1,2}, Laura Hellemans^{1,2,3}, Karolien Walgraeve¹, Jos Tournoy⁴, Peter Verhamme⁵, Peter Sinnaeve⁵, Rik Willems⁵, Walter Droogné⁵, Christophe Vandembrielle⁵, Lucas Van Aelst⁵, Thomas Vanassche⁵, Lorenz Van der Linden^{1,2}

¹Pharmacy department, University Hospitals Leuven, Belgium; ²Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; ³Research Foundation Flanders, Brussels, Belgium; ⁴Department of Public Health and Primary Care, University of Leuven and Department of Geriatric Medicine, University Hospitals Leuven, Belgium; ⁵Department of Cardiovascular Diseases, University Hospitals Leuven, and Department of Cardiovascular Sciences, University of Leuven, Belgium
Contact: Julie Hias: Julie.1.hias@uzleuven.be; Herestraat 49 3000 Leuven, Belgium

BACKGROUND & IMPORTANCE



BACKGROUND

- Cardiovascular therapies are **used frequently**, accounting for 50% of prescriptions in geriatric patients.
- They frequently cause **adverse drug events**.
- Yet, most interventional studies did not target these therapies. This might be attributed to a lack of resources, adequate training or support to perform targeted medication reviews.
- Consequently, there is a **clear need for an updated screening tool** targeting cardiovascular therapies in geriatric patients.



AIM

To update and validate the cardiovascular segment of a previously developed screening tool, the RASP list¹.

The updated **RASP_CARDIO list** was intended for use in **geriatric patients**.

RESULTS



Seventeen experts from four European countries participated in two validation rounds (Figure 1). Consensus was achieved for all statements of the RASP_CARDIO list. One new statement was added.



The final construct comprised a list of **95 statements** related to potentially inappropriate prescribing (both over- and underuse) of cardiovascular agents.

MATERIALS & METHODS

A **three step validation study** was conducted by the hospital pharmacy, geriatric medicine and cardiology departments of the University Hospitals Leuven


① **Update of RASP List (version 2014)¹**: based on literature research, other screening tools and input of end-users

② **Panel discussions** with five cardiologist and three clinical pharmacists: review of updated draft RASP_CARDIO list

③ **External validation using a modified Delphi Technique** and a panel of European hospital pharmacists, cardiologists, geriatricians and an internal medicine physician

Consensus was achieved in case of $\geq 80\%$ agreement among experts. The final construct was compared to the cardiovascular segment of the STOPP/START criteria version 2².

Figure 1: Origin of Delphi rounds participants



RASP_CARDIO ↔ STOPP/START v_2


- **90%** (29/32) of the cardiovascular statements of the second version of the STOPP/START criteria were **included in the RASP_CARDIO list**
- The RASP_CARDIO list incorporated **66 additional statements**.

CONCLUSION & RELEVANCE



The RASP_CARDIO list is an **updated and validated explicit screening tool** to **optimize cardiovascular pharmacotherapy in geriatric patients**.

Scan for poster:



REFERENCES

- 1 Van der Linden L. (2014) Eur Geriatr Med 5(3):175–180
- 2 O'Mahony D. (2015) Age Ageing 44(2):213–218

Scan for publication (including RASP_CARDIO list):

